Skip to content
ELDNEledon Pharmaceuticals, Inc.

Earnings

When Eledon Pharmaceuticals, Inc. reports, what it reported each quarter, and how the stock took the results.

55 quarters. Mar 31, 2013 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 18, after the close

Thu, Mar 18, 2027in 120 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 16 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q1 2017 n/m, Q4 2016 n/m, Q3 2016 n/m, Q2 2016 n/m
Net income
-$10.45M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q4 2023—

Latest results

  1. Q3 2026Nov 12, 2026, after the closeThe release
    Revenue
    —
    —
    Net income
    -$3.93M
    N/M
    EPS
    -$0.03
    N/M
    Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2026 operating and financial results and provided recent business highlights.
  2. Q2 2026Aug 13, 2026, after the closeThe release4.6%by the close of Aug 14
    Revenue
    —
    —
    Net income
    -$31.63M
    N/M
    EPS
    -$0.27
    N/M
  3. Q1 2026May 13, 2026, after the closeThe release+1.8%by the close of May 14
    Revenue
    —
    —
    Net income
    -$39.03M
    N/M
    EPS
    -$0.33
    N/M
  4. Q4 2025Mar 19, 2026, after the closeThe release+1.1%by the close of Mar 20
    Revenue
    —
    —
    Net income
    -$10.45M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 12, 2026 · after-hoursNov 12, 202643 d10-Q——-$0.03—
Q2 2026Jun 30, 2026Aug 13, 2026 · after-hoursAug 13, 202644 d10-Q——-$0.274.6%
Q1 2026Mar 31, 2026May 13, 2026 · after-hoursMay 13, 202643 d10-Q——-$0.33+1.8%
FY 2025
Q4 2025derivedDec 31, 2025Mar 19, 2026 · after-hoursMar 19, 202678 d10-K———+1.1%
Q3 2025Sep 30, 2025Nov 14, 2025 · after-hoursNov 14, 202545 d10-Q——-$0.217.7%
Q2 2025Jun 30, 2025Aug 14, 2025 · after-hoursAug 14, 202545 d10-Q——-$0.13+1.2%
Q1 2025Mar 31, 2025May 14, 2025 · after-hoursMay 14, 202544 d10-Q——-$0.08+1.9%
FY 2024
Q4 2024derivedDec 31, 2024Mar 20, 2025 · after-hoursMar 20, 202579 d10-K———+1.7%
Q3 2024Sep 30, 2024Nov 12, 2024 · after-hoursNov 12, 202443 d10-Q——-$0.2811.9%
Q2 2024Jun 30, 2024Aug 14, 2024 · after-hoursAug 19, 202450 d10-Q——-$0.92—
Q1 2024Mar 31, 2024May 13, 2024 · after-hoursMay 15, 202445 d10-Q——-$0.65+6.8%
Earlier years, FY 2013 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 12, 2026458564
10-QAug 13, 2026349314
10-QMay 13, 2026221702
10-KMar 19, 2026116164
10-QNov 14, 2025283275
10-QAug 14, 2025180906
10-QMay 14, 2025071582
10-KMar 20, 2025042754
10-QNov 12, 2024125622
10-QAug 19, 2024098590

Provenance

ProvenanceData status and checks

Eledon Pharmaceuticals, Inc. · CIK 1404281 · Engraved from SEC EDGAR